Nandini Verma
Affiliations: | Molecular Cell Biology | Weizmann Institute of Science, Rehovot, Israel |
Google:
"Nandini Verma"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Verma N, Vinik Y, Saroha A, et al. (2020) Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Science Advances. 6 |
| Kumar R, George B, Campbell MR, et al. (2020) HER family in cancer progression: From discovery to 2020 and beyond. Advances in Cancer Research. 147: 109-160 |
| Verma N, Müller AK, Kothari C, et al. (2020) Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research. 80: 362 |
| Kedan A, Verma N, Saroha A, et al. (2018) PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein. Cell Death & Disease. 9: 985 |
| Shin SY, Müller AK, Verma N, et al. (2018) Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. Plos Computational Biology. 14: e1006192 |
| Verma N, Müller AK, Kothari C, et al. (2016) Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Research |
| Verma N, Keinan O, Selitrennik M, et al. (2015) PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nature Communications. 6: 6064 |